<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33247916</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1945-7197</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>106</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jan</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical endocrinology and metabolism</Title>
          <ISOAbbreviation>J Clin Endocrinol Metab</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Incidence of Cabergoline-Associated Valvulopathy in Primary Care Patients With Prolactinoma Using Hard Cardiac Endpoints.</ArticleTitle>
        <Pagination>
          <StartPage>e711</StartPage>
          <EndPage>e720</EndPage>
          <MedlinePgn>e711-e720</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1210/clinem/dgaa882</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Controversy exists as to whether low-dose cabergoline is associated with clinically significant valvulopathy. Few studies examine hard cardiac endpoint data, most relying on echocardiographic findings.</AbstractText>
          <AbstractText Label="OBJECTIVES">To determine the prevalence of valve surgery or heart failure in patients taking cabergoline for prolactinoma against a matched nonexposed population.</AbstractText>
          <AbstractText Label="DESIGN">Population-based cohort study based on North East London primary care records.</AbstractText>
          <AbstractText Label="METHODS">Data were drawn from ~1.5 million patients' primary care records. We identified 646 patients taking cabergoline for &gt;6 months for prolactinoma. These were matched to up to 5 control individuals matched for age, gender, ethnicity, location, diabetes, hypertension, ischemic heart disease, and smoking status. Cumulative doses/durations of treatment were calculated. Cardiac endpoints were defined as cardiac valve surgery or heart failure diagnosis (either diagnostic code or prescription code for associated medications).</AbstractText>
          <AbstractText Label="RESULTS">A total of 18 (2.8%) cabergoline-treated patients and 62 (2.33%) controls reached a cardiac endpoint. Median cumulative cabergoline dose was 56 mg (interquartile range [IQR] 27-123). Median treatment duration was 27 months (IQR 15-46). Median weekly dose was 2.1 mg. Neither univariate nor multivariate analysis demonstrated a significant association between cabergoline treatment at any cumulative dosage/duration and an increased incidence of cardiac endpoints. In a matched analysis, the relative risk for cardiac complications in the cabergoline-treated group was 0.78 (95% CI, 0.41-1.48; P = 0.446). Reanalysis of echocardiograms for 6/18 affected cabergoline-treated patients showed no evidence of ergot-derived drug valvulopathy.</AbstractText>
          <AbstractText Label="CONCLUSIONS">The data did not support an association between clinically significant valvulopathy and low-dose cabergoline treatment and provide further evidence for a reduction in frequency of surveillance echocardiography.</AbstractText>
          <CopyrightInformation>© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Stiles</LastName>
            <ForeName>Craig Edward</ForeName>
            <Initials>CE</Initials>
            <AffiliationInfo>
              <Affiliation>Queen Mary University of London, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Saint Bartholomew's Hospital, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lloyd</LastName>
            <ForeName>Guy</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Saint Bartholomew's Hospital, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bhattacharyya</LastName>
            <ForeName>Sanjeev</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Saint Bartholomew's Hospital, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Steeds</LastName>
            <ForeName>Richard Paul</ForeName>
            <Initials>RP</Initials>
            <AffiliationInfo>
              <Affiliation>University Hospital Birmingham, Birmingham, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Cardiology, University of Birmingham, Birmingham, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boomla</LastName>
            <ForeName>Kambiz</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Primary Care and Public Health, Queen Mary University of London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bestwick</LastName>
            <ForeName>Jonathan Paul</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Centre for Environmental and Preventive Medicine, Queen Mary University of London, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Drake</LastName>
            <ForeName>William Martyn</ForeName>
            <Initials>WM</Initials>
            <AffiliationInfo>
              <Affiliation>Queen Mary University of London, London, UK.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Endocrinology, Saint Bartholomew's Hospital, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <Acronym>DH_</Acronym>
            <Agency>Department of Health</Agency>
            <Country>United Kingdom</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Endocrinol Metab</MedlineTA>
        <NlmUniqueID>0375362</NlmUniqueID>
        <ISSNLinking>0021-972X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>LL60K9J05T</RegistryNumber>
          <NameOfSubstance UI="D000077465">Cabergoline</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>J Clin Endocrinol Metab. 2021 May 13;106(6):e2452-e2454</RefSource>
          <PMID Version="1">33550413</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
          <QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077465" MajorTopicYN="N">Cabergoline</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004452" MajorTopicYN="N">Echocardiography</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006349" MajorTopicYN="N">Heart Valve Diseases</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006351" MajorTopicYN="N">Heart Valves</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006966" MajorTopicYN="N">Hyperprolactinemia</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008131" MajorTopicYN="N" Type="Geographic">London</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010911" MajorTopicYN="Y">Pituitary Neoplasms</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011320" MajorTopicYN="N">Primary Health Care</DescriptorName>
          <QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015175" MajorTopicYN="Y">Prolactinoma</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">cabergoline</Keyword>
        <Keyword MajorTopicYN="Y">cardiac valvulopathy</Keyword>
        <Keyword MajorTopicYN="Y">dopamine agonist</Keyword>
        <Keyword MajorTopicYN="Y">hyperprolactinemia</Keyword>
        <Keyword MajorTopicYN="Y">pituitary adenoma</Keyword>
        <Keyword MajorTopicYN="Y">prolactinoma</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>17</Hour>
          <Minute>4</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33247916</ArticleId>
        <ArticleId IdType="pmc">PMC7823250</ArticleId>
        <ArticleId IdType="doi">10.1210/clinem/dgaa882</ArticleId>
        <ArticleId IdType="pii">6009022</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29-38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17202453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39-46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17202454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medicines and Healthcare products Regulatory Agency. Ergot-derived dopamine agonists: risk of fibrotic reactions - GOV.UK 2008.https://www.gov.uk/drug-safety-update/ergot-derived-dopamine-agonists-risk-of-fibrotic-reactions. Accessed January 9, 2018.</Citation>
        </Reference>
        <Reference>
          <Citation>
Bogazzi F, Buralli S, Manetti L, et al. . 
Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int J Clin Pract. 2008;62(12):1864-1869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18462372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Boguszewski CL, dos Santos CM, Sakamoto KS, Marini LC, de Souza AM, Azevedo M. A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas. Pituitary. 2012;15(1):44-49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21847572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Colao A, Galderisi M, Di Sarno A, et al. . 
Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab. 2008;93(10):3777-3784.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18682513</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cordoba-Soriano JG L-OC, Hidalgo-Olivares VM, Tercero-Martinez A, Barambio-Ruiz M, Salas-Nieto J. Valvular heart disease in hyperprolactinaemic patients treated with low doses of cabergoline. Rev Esp Cardiol. 2013;66(5):3.</Citation>
        </Reference>
        <Reference>
          <Citation>
Elenkova A, Shabani R, Kalinov K, Zacharieva S. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012;167(1):17-25.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22511808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Halperin I, Aller J, Varela C, et al. . 
No clinically significant valvular regurgitation in long-term cabergoline treatment for prolactinoma. Clin Endocrinol (Oxf). 2012;77(2): 275-280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22288503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxf). 2009;70(1):104-108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19128367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kars M, Delgado V, Holman ER, et al. . 
Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab. 2008;93(9):3348-3356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18559921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lancellotti P, Livadariu E, Markov M, et al. . 
Cabergoline and the risk of valvular lesions in Endocrine disease. Eur J Endocrinol. 2008;159(1):1-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18456868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nachtigall LB, Valassi E, Lo J, et al. . 
Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010;72(1):53-58.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19508591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tan T, Cabrita IZ, Hensman D, et al. . 
Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin Endocrinol (Oxf). 2010;73(3):369-374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20550538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Vallette S, Serri K, Rivera J, et al. . 
Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary. 2009;12(3):153-157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18594989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol. 2008;159(4):R11-R14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18625690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bogazzi F, Manetti L, Raffaelli V, Lombardi M, Rossi G, Martino E. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J Endocrinol Invest. 2008;31(12):1119-1123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19246980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
De Vecchis R, Esposito C, Ariano C. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies. Herz. 2013;38(8):868-880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23743769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. J Clin Endocrinol Metab. 2019;104(2):15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30215804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Steeds RP, Stiles CE, Sharma V, Chambers JB, Lloyd G, Drake W. Echocardiography and monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia: a joint position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. Echo Res Pract. 2019;6(1):G1-G8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6391931</ArticleId>
            <ArticleId IdType="pubmed">30825409</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Gu H, Luck S, Carroll PV, Powrie J, Chambers J. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clin Endocrinol (Oxf). 2011;74(5):608-610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21198745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Auriemma RS, Pivonello R, Perone Y, et al. . 
Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013;169(3):359-366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23824978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stiles C.
 Appendix 1 discovery paper.docx. figshare. 2020. Posted November 13, 2020. 10.6084/m9.figshare.13235444.v1</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6084/m9.figshare.13235444.v1</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bhattacharyya S, Toumpanakis C, Caplin ME, Davar J. Usefulness of N-terminal pro-brain natriuretic peptide as a biomarker of the presence of carcinoid heart disease. Am J Cardiol. 2008;102(7):938-942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18805126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377-382.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19650784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Drake WM, Stiles CE, Bevan JS, et al. ; UK Cabergoline valvulopathy study group . A follow-up study of the prevalence of valvular heart abnormalities in hyperprolactinemic patients treated with cabergoline. J Clin Endocrinol Metab. 2016;101(11):4189-4194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27571182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP; UK Dopamine Agonist Valvulopathy Group . A cross-sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab. 2014;99(1):90-96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5137780</ArticleId>
            <ArticleId IdType="pubmed">24187407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP, Drake WM. A meta-analysis of the prevalence of cardiac valvulopathy in hyperprolactinemic patients treated with Cabergoline. J Clin Endocrinol Metab. 2018;104(2):523-538.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30215804</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Maione L, Garcia C, Bouchachi A, et al. . 
No evidence of a detrimental effect of cabergoline therapy on cardiac valves in patients with acromegaly. J Clin Endocrinol Metab. 2012;97(9):E1714-E1719.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22723314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Stiles CE, Steeds RP, Drake WM. Response to letter to the editor: “a meta-analysis of the prevalence of cardiac valvulopathy in patients with hyperprolactinemia treated with cabergoline”. J Clin Endocrinol Metab. 2019;104(10):4321-4322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30933270</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sherlock M, Toogood AA, Steeds R. Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Heart. 2009;95(7):522-523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19174419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Caputo C, Prior D, Inder WJ. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data. Lancet Diabetes Endocrinol. 2015;3(11):906-913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25466526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cawood TJ, Bridgman P, Hunter L, Cole D. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. Intern Med J. 2009;39(4):266-267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19402868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
D’Aloia A, Piovanelli B, Rovetta R, et al. . 
A case of iatrogenic severe mitral regurgitation. Monaldi Arch Chest Dis. 2013;80(3):133-136.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24818320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Izgi C, Feray H, Cevik C, Saltan Y, Mansuroglu D, Nugent K. Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. J Heart Valve Dis. 2010;19(6):797-800.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21214109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Moore S, Nana M, Dixon A. Severe aortic regurgitation associated with low cumulative dose cabergoline in prolactinoma: a case report. Endocrine Abstracts. 2019;65:CC6. doi:10.1530/endoabs.65.CC6</Citation>
        </Reference>
        <Reference>
          <Citation>
Steffensen C, Maegbaek ML, Laurberg P, et al. . 
Heart valve disease among patients with hyperprolactinemia: a nationwide population-based cohort study. J Clin Endocrinol Metab. 2012;97(5):1629-1634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22419729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Joseph RM, van Staa TP, Lunt M, Abrahamowicz M, Dixon WG. Exposure measurement error when assessing current glucocorticoid use using UK primary care electronic prescription data. Pharmacoepidemiol Drug Saf. 2019;28(2):179-186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6492099</ArticleId>
            <ArticleId IdType="pubmed">30264875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Singh JP, Evans JC, Levy D, et al. . 
Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83(6): 897-902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10190406</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
